These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 11525697)

  • 21. Evidence-based evaluation of preoperative vs postoperative use of low-molecular-weight heparin in preventing deep vein thrombosis in elective hip surgery.
    Ghosh A
    Arch Intern Med; 1999 Jul; 159(14):1622-3. PubMed ID: 10421287
    [No Abstract]   [Full Text] [Related]  

  • 22. A prospective observational study on the effectiveness and safety of bemiparin, first dose administered 6 h after knee or hip replacement surgery.
    Abad JI; Gómez-Outes A; Martínez-González J; Rocha E;
    Arch Orthop Trauma Surg; 2007 Oct; 127(8):665-70. PubMed ID: 17089172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
    Míka P; Behounek J; Skoták M; Nevsímal L
    Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current recommendations for extended out-of-hospital thromboprophylaxis following total hip arthroplasty.
    Krotenberg R
    Am J Orthop (Belle Mead NJ); 2004 Apr; 33(4):180-4. PubMed ID: 15132325
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Venous Thromboembolism Prophylaxis Strategies for People Undergoing Elective Total Hip Replacement: A Systematic Review and Network Meta-Analysis.
    Lewis S; Glen J; Dawoud D; Dias S; Cobb J; Griffin X; Reed M; Sharpin C; Stansby G; Barry P
    Value Health; 2019 Aug; 22(8):953-969. PubMed ID: 31426937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dabigatran: new drug. Continue to use heparin, a better-known option.
    Prescrire Int; 2009 Jun; 18(101):97-9. PubMed ID: 19637411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low-molecular-weight heparin and unfractionated heparin in prophylaxis against deep vein thrombosis in critically ill patients undergoing major surgery.
    De A; Roy P; Garg VK; Pandey NK
    Blood Coagul Fibrinolysis; 2010 Jan; 21(1):57-61. PubMed ID: 19844176
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry.
    Beyer-Westendorf J; Lützner J; Donath L; Tittl L; Knoth H; Radke OC; Kuhlisch E; Stange T; Hartmann A; Günther KP; Weiss N; Werth S
    Thromb Haemost; 2013 Jan; 109(1):154-63. PubMed ID: 23197272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Repeated Oral or Subcutaneous LMWH Has similar Antithrombotic Activity in a Rat Venous Thrombosis Model: Antithrombotic Activity Correlates With Heparin on Endothelium When Orally Administered.
    Hiebert LM
    J Cardiovasc Pharmacol Ther; 2017 May; 22(3):264-272. PubMed ID: 27653610
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective.
    Hull RD; Raskob GE; Pineo GF; Feldstein W; Rosenbloom D; Gafni A; Green D; Feinglass J; Trowbridge AA; Elliott CG
    Arch Intern Med; 1997 Feb; 157(3):298-303. PubMed ID: 9040296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
    Raskob G; Cohen AT; Eriksson BI; Puskas D; Shi M; Bocanegra T; Weitz JI
    Thromb Haemost; 2010 Sep; 104(3):642-9. PubMed ID: 20589317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Wound complications following rivaroxaban administration: a multicenter comparison with low-molecular-weight heparins for thromboprophylaxis in lower limb arthroplasty.
    Jameson SS; Rymaszewska M; Hui AC; James P; Serrano-Pedraza I; Muller SD
    J Bone Joint Surg Am; 2012 Sep; 94(17):1554-8. PubMed ID: 22832942
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative effectiveness of low-molecular-weight heparins versus other anticoagulants in major orthopedic surgery: a systematic review and meta-analysis.
    Sobieraj DM; Coleman CI; Tongbram V; Chen W; Colby J; Lee S; Kluger J; Makanji S; Ashaye A; White CM
    Pharmacotherapy; 2012 Sep; 32(9):799-808. PubMed ID: 22744711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical experience with ximelagatran in orthopaedic surgery.
    Eriksson B
    Drugs; 2004; 64 Suppl 1():27-35. PubMed ID: 15586625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Subcutaneous low-molecular weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement? Fraxiparine Oral Anticoagulant Study Group.
    Hamulyák K; Lensing AW; van der Meer J; Smid WM; van Ooy A; Hoek JA
    Thromb Haemost; 1995 Dec; 74(6):1428-31. PubMed ID: 8772214
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Thrombosis prophylaxis in orthopaedic surgery: considerations and uncertainties].
    Ettema HB; Hoppener MR; Büller HR; Henny ChP; Verheyen CC
    Ned Tijdschr Geneeskd; 2003 Sep; 147(38):1842-7. PubMed ID: 14533495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimal duration of prophylaxis for venous thromboembolism following total hip arthroplasty and total knee arthroplasty.
    Friedman RJ
    J Am Acad Orthop Surg; 2007 Mar; 15(3):148-55. PubMed ID: 17341671
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial.
    Heit JA; Elliott CG; Trowbridge AA; Morrey BF; Gent M; Hirsh J
    Ann Intern Med; 2000 Jun; 132(11):853-61. PubMed ID: 10836911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Symptomatic in-hospital deep vein thrombosis and pulmonary embolism following hip and knee arthroplasty among patients receiving recommended prophylaxis: a systematic review.
    Januel JM; Chen G; Ruffieux C; Quan H; Douketis JD; Crowther MA; Colin C; Ghali WA; Burnand B;
    JAMA; 2012 Jan; 307(3):294-303. PubMed ID: 22253396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.